RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

S. H. Chen,Xueqian Gong,Youyan Zhang,R.D. Van Horn,Tinggui Yin,Lysiane Huber,Teresa Burke,Jason R. Manro,Phillip Iversen,Wenjuan Wu,Shripad V. Bhagwat,Richard P. Beckmann,Ramon V. Tiu,Sean Buchanan,S. B. Peng

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

2018

S. H. Chen
Xueqian Gong
Youyan Zhang
R.D. Van Horn
Tinggui Yin
Lysiane Huber
Teresa Burke
Jason R. Manro
Phillip Iversen
Wenjuan Wu
Shripad V. Bhagwat
Richard P. Beckmann
Ramon V. Tiu
Sean Buchanan
S. B. Peng

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

Keywords:

Cyclin D1
Cancer research
Molecular biology
Cancer
Mutant
CDK4/6 Inhibition
Abemaciclib
Biology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations